Safety profile of sparfloxacin in the treatment of respiratory tract infections

Journal of Antimicrobial Chemotherapy

Volumn 37, Issue SUPPL. A, 1996, Pages 145-160

  Rubinstein, Ethan ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ERYTHROMYCIN; OFLOXACIN; SPARFLOXACIN;

ABDOMINAL PAIN; ADULT; AGED; ANGIONEUROTIC EDEMA; ARTHRALGIA; ARTICLE; ASTHMA; CARDIOTOXICITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALAISE; MYALGIA; NEUROTOXICITY; PHASE 3 CLINICAL TRIAL; PHOTOSENSITIVITY; PNEUMONIA; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; CLINICAL TRIALS, PHASE III; COMMUNITY-ACQUIRED INFECTIONS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROQUINOLONES; HUMANS; LUNG DISEASES, OBSTRUCTIVE; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; QUINOLONES; RANDOMIZED CONTROLLED TRIALS; RESPIRATORY TRACT INFECTIONS;

EID: 0029953037     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/37.1.145     Document Type: Article

References (14)

1. Azoulay-Dupuis, E., Valee, E., Veber, B., Bedos, J. P., Bauchet, J. & Pocidalo, J. J. (1992). In vivo efficacy of a new fluoroquinolone, sparfloxacin, against penicillin-susceptible and resistant and multiresistant strains of Streptococcus pneumoniae in a mouse model of pneumonia. Antimicrobial Agents and Chemotherapy 36, 2698-703.
2. Blum, M. D., Graham, D. J. & McCloskey, C. A. (1994). Temafloxacin syndrome: review of 95 cases. Clinical Infectious Diseases 18, 946-50.
3. Bowie, W. R., Willetts, V. & Jewesson, P. J. (1989). Adverse reactions in a dose ranging study with a new long acting fluoroquinolone, fleroxacin. Antimicrobial Agents and Chemotherapy 33, 1778-82.
4. Davey, P. G. (1989). Post marketing surveillance of the quinolones. Reviews of Infectious Diseases 11, Suppl. 5, S1402-7.
5. Hooper, D. C. & Wolfson, J. S. (1989a). Adverse effects of quinolone antimicrobial agents. In Quinolone Antimicrobial Agents (Wolfson J. S. & Hooper, D. C., Eds), pp. 249-71. American Society for Microbiology, Washington, DC.
6. Hooper, D.C. & Wolfson, J.S. (1989b). Treatment of genitourinary tract infections with fluoroquinolones: clinical efficacy in genital infections and adverse effects. Antimicrobial Agents and Chemotherapy 33, 1662-7.
7. McCue, J. D. (1994). Antimicrobial therapy for the vulnerable elder: clinical overview. Infectious Diseases in Clinical Practice 3, 12-22.
8. Montamat, S. C., Cusack, B. J. & Vestal, R. E. (1989). Management of drug therapy in the elderly. New England Journal of Medicine 321, 303-9.
9. Norrby, S. R. (1991). Side effects of quinolones: comparisons between quinolones and other antibiotics. European Journal of Clinical Microbiology and Infectious Diseases Special Issue, 158-63.
10. Norrby, S. R. & Pernet, A. G. (1991). Assessment of adverse events during development: experience with temafloxacin. Journal of Antimicrobial Chemotherapy 28, Suppl. C, 111-9.
11. Ouslander, J. G. (1981). Drug therapy in the elderly. Annals of Internal Medicine 95, 711-22.
12. Ramsay, C. A. & Obershkova, E. (1974). Photosensitivity from nalidixic acid. British Journal of Dermatology 91, 523-8.
13. Rubinstein, E., Potgieter, P., Davey, P. & Norrby, S. R. (1994). The use of fluoroquinolones in neutropenic patients-analysis of adverse effects. Journal of Antimicrobial Chemotherapy 34, 7-19.
14. Wolfson, J. S. & Hooper, D. C. (1991). Overview of fluoroquinolone safety. American Journal of Medicine 91, Suppl. 6A, 153-61.